List of Receptors
Receptor | Organism | Cell type | Mechanism of raft association | Methods used to detect raft association | Functional implication |
---|---|---|---|---|---|
Protease-activated receptor type 1 (PAR-1) |
Aortic endothelial cells 1; HEK-293 2, COS-7 cells 2; Endothelial cells 3 |
Bound caveolin-1 2 |
Detergent-free 1, 2; Immunoaffinity isolation 1; Immunoprecipitation 2; Confocal microscopy 2 |
Filipin treatment attenuates Myosine light chain phosphorylation and stress fiber formation 1; Agonist treatment did not change receptor localization in raft 2; PAR-1 signaling by APC is lost in caveolin-1 deficient cells 3; Lipid raft/caveolae is essential for N-terminal truncation of PAR1 which is needed for its activation and PAR1-mediated signaling by APC 3 |
|
Protease-activated receptor type 2 PAR-2 |
n.a |
Western immunoblot 4; Detergent-dependent 5; Immunofluorescence confocal microscopy 5 |
Receptor activation and barrier abrogation leads to receptor internalization 4; MβCD and filipin treatment in addition to caveolin-1 silencing reduced TF-VIIa-mediated cleavage of PAR-2 and IL-8 gene expression 5 |
||
Serotonin 5-HT 7 receptor |
Human 6 |
HeLa cells 6 |
n.a |
Sphingomyelin depletion |
Fumonisin B1 and PDMP treatment decrease remarkably binding of 5-HT to 5-HT7 receptor 6 |
Serotonin 5-HT1A receptor |
Mouse 7 |
Palmitoylation 7 |
Signaling reduces in cyclodextrin treated and palmitoylated-deficient cells 7 |
||
Serotonin 5-HT2A receptor |
Rat 8 |
Tail artery 8 |
n.a |
Detergent-free 8 |
Cyclodextrin reduce agonist response 8 |
Somatostatin receptor type 2 |
Human 9 |
Glioma cells 9 |
n.a |
Receptor internalized via caveolin-positive endosomal vesicles after ligand binding 9 |
|
Sphingosine 1-phosphate receptor |
Detergent-free 10 |
Agonist induced translocation to the caveolae, Caveolin overexpression inhibited receptor function 10 |
|||
Thyrotropin receptor |
n.a |
Receptors move out of raft upon activation 12; MβCD treatment did not alter cAMP accumulation 13; Cav-1 knockdown increased cAMP accumulation 14 |
|||
Thyrotropin-releasing hormone receptor |
n.a |
Sucrose gradient centrifugation and immunoblotting 15 |
Agonist induced receptor movement in to low density vesicular fraction 15; MβCD treatment inhibited Gq/G11α tyrosine phosphorylation 16 |
||
Vasopressin receptor |
- |
Endothelium of tail artery 8; Thick ascending limb of the loop of Henle 18 |
n.a |
MβCD treatment reduced receptor function8; Lipid raft is required for receptor-induced trafficking 18 |